A Phase 4 interventional study of EXPAREL 20 mL and EXPAREL 40 mL in Postsurgical Pain, Analgesia and Prostatectomy, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.
Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 75th largest by enrollment, is one of 6 that started in 2012, is one of 52 in phase 4, and was the 1st registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Tianjin First Central Hospital · Sites in China
Ages 18–80
Texas Scottish Rite Hospital for Children · Sites in United States
Ages 13–21
Boston Children's Hospital · Sites in United States
Ages 10–17
Texas Tech University Health Sciences Center · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 75 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 16 · Phase 4 52
First in 2012; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 80 across the 93 interventional studies. Of the 61 that completed or were terminated, 41 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
25 studies in Pain, Postoperative by Pacira BioSciences, Inc.: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 25 studies in Pain, Postoperative by Pacira BioSciences, Inc., this one is the 19th largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2012, is one of 6 in phase 4, and was the 13th registered.
Pacira BioSciences, Inc.’s Pain, Postoperative studies by the year they started, since 2004.
8 of the studies testing Liposomal Bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT06271265Pacira Pharmaceuticals, IncStudy to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery | 2027-01 |
| NCT07689162Washington University School of MedicineLiposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, from their registry updates:
Among Pacira BioSciences, Inc.’s 25 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy.
Assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to provide prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy. The primary endpoint is the duration of abdominal analgesia from the infiltration into the TAP as measured by the time to the subject's first postsurgical opioid administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mL (266 mg) undiluted EXPAREL with 133 mg infiltrated on each the right and left side of the abdomen.
Drug: EXPAREL 20 mL
20 mL (266 mg) EXPAREL diluted with an equal volume of preservative-free 0.9% normal saline to a total of 40 mL and infiltrated equally to the right and left side of the abdomen.
Drug: EXPAREL 40 mL
EXPAREL 266 mg (undiluted)
Also known as: bupivacaine liposome injectable suspension
EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
Also known as: bupivacaine liposome injectable suspension
The Duration of Abdominal Analgesia From Infiltration Into the TAP
Time frame: First postsurgical administration of an opioid
Subject Reported Postsurgical Pain
11-point numeric rating scale (NRS) (0-10, where 0=no pain, 10=worst possible pain)
Time frame: 1, 2, 6, 12, 24, 48, 72, 96 hours and 10 days after TAP
Physician/Healthcare Professional Assessed Postsurgical Pain
11-point NRS (0-10, 0=no pain, 10=worst possible pain)
Time frame: 1, 2, 6, 12, 24 hours after TAP
Total Postsurgical Oxycodone/Acetaminophen Consumption From Hospital Discharge Through Hour 96.
Number of pills
Time frame: 48, 72, 96 hours
Incidence of Prespecified Opioid-related Adverse Events
Number of subjects
Time frame: Until hospital discharge order was written, anticipated at 24 hours.
Overall Rating of Subject Satisfaction With Postsurgical Pain Control
Mean of subject satisfaction offered on a 5-point Likert scale (1 = extremely dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = extremely satisfied)
Time frame: 24 hours, 72 hours, and day 10
| Milestone | EXPAREL 20 mL | EXPAREL 40 mL |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| hours | EXPAREL 20 mL | EXPAREL 40 mL |
|---|---|---|
| The Duration of Abdominal Analgesia From Infiltration Into the TAP | 0.39 (0.27 to 0.60) | 0.44 (0.40 to 0.58) |
11-point numeric rating scale (NRS) (0-10, where 0=no pain, 10=worst possible pain)
| units on a scale | EXPAREL 20 mL | EXPAREL 40 mL |
|---|---|---|
| 1 hour after TAP | 4.4 ± 2.57 | 5.3 ± 2.35 |
| 2 hours after TAP | 3.1 ± 1.5 | 3.9 ± 2.15 |
| 6 hours after TAP | 2.4 ± 1.57 | 3.0 ± 2.10 |
| 12 hours after TAP | 2.5 ± 2.12 | 2.2 ± 1.60 |
| 24 hours after TAP | 1.8 ± 1.75 | 2.5 ± 1.68 |
| 48 hours after TAP | 2.0 ± 1.54 | 2.5 ± 2.61 |
| 72 hours after TAP | 1.8 ± 1.64 | 1.9 ± 1.83 |
| 96 hours after TAP | 1.1 ± 1.08 | 1.7 ± 2.06 |
| Day 10 after TAP | 0.00 ± 0.00 | 1.0 ± 1.55 |
11-point NRS (0-10, 0=no pain, 10=worst possible pain)
| units on a scale | EXPAREL 20 mL | EXPAREL 40 mL |
|---|---|---|
| 1 hour after TAP | 4.2 ± 2.33 | 5.3 ± 2.35 |
| 2 hours after TAP | 2.9 ± 1.56 | 3.9 ± 2.15 |
| 6 hours after TAP | 2.4 ± 1.57 | 3.0 ± 2.10 |
| 12 hours after TAP | 2.6 ± 2.07 | 2.2 ± 1.33 |
| 24 hours after TAP | 1.8 ± 1.75 | 2.5 ± 1.68 |
Number of pills
| Number of tablets | EXPAREL 20 mL | EXPAREL 40 mL |
|---|---|---|
| 48 hours | 1.9 ± 2.11 | 2.2 ± 2.12 |
| 72 hours | 2.8 ± 3.21 | 3.4 ± 3.75 |
| 96 hours | 3.7 ± 4.25 | 4.8 ± 5.33 |
Number of subjects
| Number of subjects | EXPAREL 20 mL | EXPAREL 40 mL |
|---|---|---|
| Incidence of Prespecified Opioid-related Adverse Events | 0 | 0 |
Mean of subject satisfaction offered on a 5-point Likert scale (1 = extremely dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = extremely satisfied)
| Participants | EXPAREL 20 mL | EXPAREL 40 mL |
|---|---|---|
| 24 hours- satisfied | 4 | 5 |
| 24 hours- extremely satisfied | 8 | 7 |
| 72 hours - satisfied | 4 | 4 |
| 72 hours - extremely satisfied | 7 | 7 |
| Day 10 - satisfied | 3 | 4 |
| Day 10- extremely satisfied | 8 | 7 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EXPAREL 20 mL | — | 3/12 (25%) | 0/12 (0%) |
| EXPAREL 40 mL | — | 0/12 (0%) | 1/12 (8.3%) |
| Event | EXPAREL 20 mL | EXPAREL 40 mL |
|---|---|---|
| Post-procedural HematomaVascular disorders | 1/12 | 0/12 |
| Pulmonary EmbolismVascular disorders | 1/12 | 0/12 |
| PyrexiaGeneral disorders | 1/12 | 0/12 |
| Event | EXPAREL 20 mL | EXPAREL 40 mL |
|---|---|---|
| Joint StiffnessMusculoskeletal and connective tissue disorders | 0/12 | 1/12 |
| Joint SwellingMusculoskeletal and connective tissue disorders | 0/12 | 1/12 |
| Age, Categorical(Participants) | EXPAREL 20 mL | EXPAREL 40 mL | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 9 | 15 |
| >=65 years | 6 | 3 | 9 |
| Age, Continuous(years) | EXPAREL 20 mL | EXPAREL 40 mL | Total |
|---|---|---|---|
| Mean | 60.7 ± 7.24 | 61.7 ± 7.01 | 61.2 ± 6.99 |
| Sex: Female, Male(Participants) | EXPAREL 20 mL | EXPAREL 40 mL | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 12 | 12 | 24 |
| Region of Enrollment(participants) | EXPAREL 20 mL | EXPAREL 40 mL | Total |
|---|---|---|---|
| United States | 12 | 12 | 24 |
The record gives a start of Mar 2012, a primary completion of May 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine